News

Quest's Haystack MRD Test Gains NY Approval, Expands Access

Quest's Haystack MRD Test Gains NY Approval, Expands Access

Quest Diagnostics' Expansion in New York

June 24, 2026, marked a noteworthy day for Quest Diagnostics as they got the green light from New York's Health Department to roll out their Haystack MRD® test statewide. You think about all the red tape a lab test has to cut through in New York—it's a pretty big cigar moment for Quest. This is a state known for its rigorous standards. Getting approval here isn't just a nod—it's a full-on embrace, saying the offering is up to scratch.

Why the Haystack MRD Test Matters

Quest Diagnostics, riding under the ticker symbols like NYSE:DGX, isn't just making noise—they're shouting relevance. The Haystack MRD test isn't your run-of-the-mill lab procedure. It's a liquid biopsy test, eyeing those nasty little culprits—minimal residual disease—in solid tumor cancers. For oncologists, this means spotting residual disease is less like playing 'Where's Waldo' and more like having an eagle eye. This creates a big potential for catching recurrence before it's staring us down in the rearview mirror.

“This approval represents the culmination of our many years of hard work and commitment to delivering a highly accurate test that can meaningfully improve patient care,” Dan Edelstein, VP and GM for Haystack Oncology, mentions.

Clinical Impact: More Than Just Numbers

But hey, let’s not forget the human element. This test goes beyond the slides and slides of data. For patients, especially those with rough-riding solid tumors, having this test means more than just words on paper. It's a chance at getting ahead of the dreaded beast of recurrence. Dr. Andrea Cercek and her team confirmed that with Haystack MRD, you aren't just looking at months saved; you're looking at lives impacted. Imagine going from over six months to just 1.4 months to detect complete clinical response compared to imaging methods. That's like winning the lottery in time savings.

Breaking Ground and Setting Standards

What’s surreal is the level of clinical utility this test packs, as demonstrated in rigorous settings. When Quest talks about Haystack Oncology, they speak of innovation stemming from over 20 years of head-to-ground collaboration with Johns Hopkins School of Medicine. When science and practice band together like this, it prompts action that stretches beyond mere headlines.

Quest Diagnostics' Broader Vision

Quest, the company pulling in this win, isn't a stranger to wrapping diagnostics like a tight knit gift. Spanning across half the physicians and hospitals in the U.S.—do they have their finger on the pulse, or do they have the pulse? They serve roughly one in three American adults each year—a staggering stat, practically serving like our healthcare compass.

With most tests now authorized across all 50 states, Quest’s Haystack MRD test stands as a pillar in diagnostic innovation. While the healthcare enterprise trains its sights on simplifying patient solutions, the stakes continue to climb for improving patient outcomes.

Potential investors may view this as Quest solidifying its role as a pace-setter in diagnostic advancements. However, tossing NYSE:DGX out there is less about market bullishness and more about the responsibility for driving headway in healthcare.

Future Prospects and Clinical Integration

Haystack's not just another test—it’s a model for tomorrow. The FDA graced it with a Breakthrough Device Designation, a move that’s both a pat on the back and a tap on the shoulder, urging continued excellence. It’s high time ventures like Haystack become grounded as regulars in clinical settings. Every advance pushes us further down the lane of a healthier world, one decisive ctDNA detect at a time.

While Quest Diagnostics sets the pace for rolling out smarter diagnostics, folks outside may wonder, will it translate to concrete growth for NYSE:DGX? Or is this more about solid footing in the ever-evolving healthcare market landscape? No crystal ball, but whichever way it spins out, the game’s poised to change.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Teva’s R&D Exit Puts Disclosure Questions in Focus

Updated Category News Views 92

An abrupt departure in the drug business is never just an HR memo. Teva Pharmaceutical Industries shares reportedly dropped about 8.74% after Eric Hughes, the company’s executive vice president of Global R&D and chief medical officer, left effective immediately. That kind of move rattles investors because R&D leadership is not decorative furniture at a pharmaceutical...

Continue Reading
ECW Puts $52 Million Behind Learning Through Crisis

Updated Category News Views 66

A reserve fund for a classroom is not glamorous, but it may be the smartest detail in this whole $52 million commitment. Education Cannot Wait has announced support for more than 300,000 children in Lebanon, Myanmar and South Sudan, where war, flooding and displacement have ripped ordinary schooling apart. The money is meant to restore learning, provide catch-up classes...

Continue Reading
Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire

Updated Category News Views 48

A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...

Continue Reading
Why Insurance Must Change as Family Assets Keep Growing

Updated Category News Views 73

A policy bought in the starter-home years can turn stale quietly while everything around it gets bigger, pricier and more complicated. That is the uncomfortable little truth behind Daniel C. DiCocco's discussion in HelloNation: families often treat insurance as a box checked long ago, even as they add property, savings, debt, children and fresh responsibilities. Static...

Continue Reading
Tigerlily Brings HIV Information to Women’s Health

Updated Category News Views 37

A stubborn information gap is exactly where Tigerlily Foundation is planting its flag. The nonprofit’s new national HIV education and awareness campaign, THE POWER OF U, expands work that began in breast cancer advocacy into another area where women need clear facts, trusted voices, and room to speak without being shamed for needing answers. This is not a story that...

Continue Reading
Rosalind Franklin University’s $23.8M Scholarship Win

Updated Category News Views 80

Twenty-three million dollars can disappear fast in graduate health education, which is exactly why Rosalind Franklin University’s campaign result deserves more than a polite round of applause. The university’s five-year Empowering Scholars effort closed in June 2026 with $23,836,272 raised, clearing its $20 million target by roughly 19%. In a world where institutions...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 58

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 79

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
Epilepsy Campaign Puts Patient Voices Before Investors

Updated Category News Views 46

An epilepsy diagnosis can turn ordinary family routines into a maze overnight, which is why awareness work deserves more than the usual polite nod and a colored ribbon. Mediaplanet's national Epilepsy Awareness campaign, launched November 20, 2026, brings the subject into a USA TODAY print insert and related digital coverage during Epilepsy Awareness Month. That reach...

Continue Reading
Niron's $1.8B Alabama Bet Carries Big Magnet Stakes

Updated Category News Views 54

A Huge Factory Claim Needs More Than Applause A magnet company just tossed a very large number onto Alabama's economic-development table. Niron Magnetics says it plans a $1.8 billion investment in the state that would create 700 jobs. That is not pocket change, not a ribbon-cutting trinket, and not the sort of announcement investors should breeze past between earnings...

Continue Reading

Top 5 Most Recently Viewed Articles

PAPZIMEOS Emerges as the Go-To Treatment for RRP Patients

Updated Category News Views 104

PAPZIMEOS: A Promising New Standard for RRP Therapy PAPZIMEOS (zopapogene imadenovec) has gained recognition as an innovative treatment for adults suffering from recurrent respiratory papillomatosis (RRP). This breakthrough comes following the publication of a consensus paper authored by 16 leading experts in the field. Sponsored by the Recurrent Respiratory...

Continue Reading
Ollie's Bargain Outlet Reports Encouraging Q2 Results

Updated Category News Views 159

Ollie's Bargain Outlet Achieves Strong Q2 Performance Ollie's Bargain Outlet Holdings, Inc. (NASDAQ: OLLI) has made headlines recently as its shares experience fluctuations in the market. The company revealed impressive second-quarter adjusted earnings per share of 99 cents, surpassing analyst expectations of 94 cents. The quarterly sales reached $679.556 million, marking...

Continue Reading
Fivecast Introduces Groundbreaking Discovery Solution for OSINT

Updated Category News Views 184

Fivecast Unveils Discovery Solution to Combat Global Threats In today's rapidly evolving landscape of global threats, Fivecast, a prominent provider of advanced open-source intelligence (OSINT) solutions, has rolled out an innovative Discovery solution designed to assist analysts and investigators in both government and corporate settings. By elevating the speed and...

Continue Reading
Zen Technologies USA Advances Military Training with AI Simulations

Updated Category News Views 224

Zen Technologies USA Showcases Cutting-Edge AI Simulations Zen Technologies USA is set to revolutionize military training capabilities with its next-generation AI-enabled live and virtual simulation solutions. By enabling high-fidelity training for ground and naval forces, these innovations aim to accelerate the readiness of military units while significantly reducing...

Continue Reading
Sectra and Siemens Healthineers Transform Radiology Workflows

Updated Category News Views 494

Revolutionizing Radiology with Innovative Integrations International medical imaging IT and cybersecurity company Sectra (STO: SECT B) and Siemens Healthineers AG have formed a pivotal collaboration aimed at enhancing diagnostic capabilities in the radiology field. This initiative seeks to improve patient care by enabling seamless access to advanced imaging technologies....

Continue Reading